Equity Elixir? Concord Looks to Raise Funds Without Breaking a Sweat

Concord Drugs Limited, an industry leading formulating company in pharmaceuticals and contract manufacturer, announced today that the Board of Directors will meet on June 27, 2025, to consider a proposal for raising funds through preferential allotment of equity shares.

 

The firm announced the development in a BSE regulatory filing, further stating that the board would also look at other strategic matters with the leave of the chair. While the exact amount of the proposed fundraising has yet to be specified, the move will probably be used to drive Concord's growth plans, work capital requirements, or expansion initiatives.

 

This comes after approval was given to the audited FY25 financial results of the company, and is consistent with a broader trend of small-cap pharma firms tapping into the equity markets in order to strengthen balance sheets as demand for cheap generics and contract manufacturing services keeps rising.

 

Shareholders and analysts will be eager to learn more after the board meeting, especially issue pricing, investor demand, and proceeds deployment.

 

Sources: Rediff MoneyWiz, Economic Times, Concord Drugs Ltd.